Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 15/20 | 0.36 |
| ▸ | CPT2 | P23786 | 11/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.34 |
| ▸ | CPT1B | Q92523 | 5/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729068 | 0.93 | CPT1A (0.36) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| SCHEMBL2726425 | 0.92 | HCRTR1 (0.36) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| SCHEMBL2726429 | 0.92 | HCRTR1 (0.36) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| SCHEMBL2726168 | 0.92 | CPT1A (0.36) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| Fumaric Acid SCHEMBL2732804 | 0.89 | HCRTR1 (0.34) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| SCHEMBL2726475 | 0.89 | HCRTR1 (0.34) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| SCHEMBL2726641 | 0.85 | HCRTR1 (0.38) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| SCHEMBL6465560 | 0.85 | HCRTR1 (0.38) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| SCHEMBL2726642 | 0.85 | HCRTR1 (0.38) | CPT1ACPT2HCRTR1HCRTR2CPT1B | |
| SCHEMBL2726639 | 0.85 | HCRTR1 (0.38) | CPT1ACPT2HCRTR1HCRTR2CPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |